Comparison of methotrexate polyglutamylation in L1210 leukemia cells when influx is mediated by the reduced folate carrier or the folate receptor. Lack of evidence for influx route-specific effects

Michael J. Spinella, Kevin E. Brigle, Sarah J. Freemantle, Esteban E. Sierra, I. David Goldman

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

We previously described a methotrexate-resistant L1210 cell line (MTX(r)A) that lacks a functional reduced folate carrier and does not appreciably express the folate receptor. In the present study, we utilized MTX(r)A cell lines stably transfected with cDNAs encoding either the folate receptor or the reduced folate carrier to investigate the influence of the route of folate influx on the rate and extent of methotrexate polyglutamylation. At an extracellular methotrexate concentration of 0.1 μM, influx in the folate receptor transfectant (MTX(r)A-TF1) and in the reduced folate carrier transfectant (MTX(r)A-R1) was equal and methotrexate polyglutamates accumulated at an identical rate, but the onset was delayed until dihydrofolate reductase was saturated with the monoglutamate (~3 hr). The onset of polyglutamate formation was immediate and identical among the lines in cells pretreated with the lipophilic dihydrofolate reductase inhibitor trimetrexate to block methotrexate binding to dihydrofolate reductase. The spectra of individual methotrexate polyglutamates that accumulated were similar, with the tetraglutamate present as the predominant form. A 100-fold higher methotrexate concentration was required to detect methotrexate uptake and polyglutamylation in the transport defective parent MTX(r)A line, demonstrating that diffusion or an unidentified low affinity route also supports polyglutamylation. Since the folate receptor and the reduced folate carrier achieve nearly identical rates of polyglutamylation despite very different mechanisms of methotrexate delivery, the data suggest that transport-mediated substrate channeling to folylpolyglutamate synthetase is unlikely to play a role in tetrahydrofolate metabolism. This study supports the notion that it is the intracellular concentration of methotrexate achieved within the cell that drives polyglutamylation irrespective of its route of entry.

Original languageEnglish (US)
Pages (from-to)703-712
Number of pages10
JournalBiochemical Pharmacology
Volume52
Issue number5
DOIs
StatePublished - Sep 13 1996

Fingerprint

Reduced Folate Carrier Protein
Leukemia L1210
Folic Acid
Methotrexate
Tetrahydrofolate Dehydrogenase
Trimetrexate
Cells
Polyglutamic Acid
Folic Acid Antagonists
Cell Line
Metabolism
Complementary DNA

Keywords

  • folate receptor
  • L1210
  • methotrexate
  • polyglutamylation
  • reduced folate carrier
  • transport

ASJC Scopus subject areas

  • Pharmacology

Cite this

Comparison of methotrexate polyglutamylation in L1210 leukemia cells when influx is mediated by the reduced folate carrier or the folate receptor. Lack of evidence for influx route-specific effects. / Spinella, Michael J.; Brigle, Kevin E.; Freemantle, Sarah J.; Sierra, Esteban E.; Goldman, I. David.

In: Biochemical Pharmacology, Vol. 52, No. 5, 13.09.1996, p. 703-712.

Research output: Contribution to journalArticle

@article{269f53bfc91444e19139f39fd855fe9f,
title = "Comparison of methotrexate polyglutamylation in L1210 leukemia cells when influx is mediated by the reduced folate carrier or the folate receptor. Lack of evidence for influx route-specific effects",
abstract = "We previously described a methotrexate-resistant L1210 cell line (MTX(r)A) that lacks a functional reduced folate carrier and does not appreciably express the folate receptor. In the present study, we utilized MTX(r)A cell lines stably transfected with cDNAs encoding either the folate receptor or the reduced folate carrier to investigate the influence of the route of folate influx on the rate and extent of methotrexate polyglutamylation. At an extracellular methotrexate concentration of 0.1 μM, influx in the folate receptor transfectant (MTX(r)A-TF1) and in the reduced folate carrier transfectant (MTX(r)A-R1) was equal and methotrexate polyglutamates accumulated at an identical rate, but the onset was delayed until dihydrofolate reductase was saturated with the monoglutamate (~3 hr). The onset of polyglutamate formation was immediate and identical among the lines in cells pretreated with the lipophilic dihydrofolate reductase inhibitor trimetrexate to block methotrexate binding to dihydrofolate reductase. The spectra of individual methotrexate polyglutamates that accumulated were similar, with the tetraglutamate present as the predominant form. A 100-fold higher methotrexate concentration was required to detect methotrexate uptake and polyglutamylation in the transport defective parent MTX(r)A line, demonstrating that diffusion or an unidentified low affinity route also supports polyglutamylation. Since the folate receptor and the reduced folate carrier achieve nearly identical rates of polyglutamylation despite very different mechanisms of methotrexate delivery, the data suggest that transport-mediated substrate channeling to folylpolyglutamate synthetase is unlikely to play a role in tetrahydrofolate metabolism. This study supports the notion that it is the intracellular concentration of methotrexate achieved within the cell that drives polyglutamylation irrespective of its route of entry.",
keywords = "folate receptor, L1210, methotrexate, polyglutamylation, reduced folate carrier, transport",
author = "Spinella, {Michael J.} and Brigle, {Kevin E.} and Freemantle, {Sarah J.} and Sierra, {Esteban E.} and Goldman, {I. David}",
year = "1996",
month = "9",
day = "13",
doi = "10.1016/0006-2952(96)00347-4",
language = "English (US)",
volume = "52",
pages = "703--712",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Comparison of methotrexate polyglutamylation in L1210 leukemia cells when influx is mediated by the reduced folate carrier or the folate receptor. Lack of evidence for influx route-specific effects

AU - Spinella, Michael J.

AU - Brigle, Kevin E.

AU - Freemantle, Sarah J.

AU - Sierra, Esteban E.

AU - Goldman, I. David

PY - 1996/9/13

Y1 - 1996/9/13

N2 - We previously described a methotrexate-resistant L1210 cell line (MTX(r)A) that lacks a functional reduced folate carrier and does not appreciably express the folate receptor. In the present study, we utilized MTX(r)A cell lines stably transfected with cDNAs encoding either the folate receptor or the reduced folate carrier to investigate the influence of the route of folate influx on the rate and extent of methotrexate polyglutamylation. At an extracellular methotrexate concentration of 0.1 μM, influx in the folate receptor transfectant (MTX(r)A-TF1) and in the reduced folate carrier transfectant (MTX(r)A-R1) was equal and methotrexate polyglutamates accumulated at an identical rate, but the onset was delayed until dihydrofolate reductase was saturated with the monoglutamate (~3 hr). The onset of polyglutamate formation was immediate and identical among the lines in cells pretreated with the lipophilic dihydrofolate reductase inhibitor trimetrexate to block methotrexate binding to dihydrofolate reductase. The spectra of individual methotrexate polyglutamates that accumulated were similar, with the tetraglutamate present as the predominant form. A 100-fold higher methotrexate concentration was required to detect methotrexate uptake and polyglutamylation in the transport defective parent MTX(r)A line, demonstrating that diffusion or an unidentified low affinity route also supports polyglutamylation. Since the folate receptor and the reduced folate carrier achieve nearly identical rates of polyglutamylation despite very different mechanisms of methotrexate delivery, the data suggest that transport-mediated substrate channeling to folylpolyglutamate synthetase is unlikely to play a role in tetrahydrofolate metabolism. This study supports the notion that it is the intracellular concentration of methotrexate achieved within the cell that drives polyglutamylation irrespective of its route of entry.

AB - We previously described a methotrexate-resistant L1210 cell line (MTX(r)A) that lacks a functional reduced folate carrier and does not appreciably express the folate receptor. In the present study, we utilized MTX(r)A cell lines stably transfected with cDNAs encoding either the folate receptor or the reduced folate carrier to investigate the influence of the route of folate influx on the rate and extent of methotrexate polyglutamylation. At an extracellular methotrexate concentration of 0.1 μM, influx in the folate receptor transfectant (MTX(r)A-TF1) and in the reduced folate carrier transfectant (MTX(r)A-R1) was equal and methotrexate polyglutamates accumulated at an identical rate, but the onset was delayed until dihydrofolate reductase was saturated with the monoglutamate (~3 hr). The onset of polyglutamate formation was immediate and identical among the lines in cells pretreated with the lipophilic dihydrofolate reductase inhibitor trimetrexate to block methotrexate binding to dihydrofolate reductase. The spectra of individual methotrexate polyglutamates that accumulated were similar, with the tetraglutamate present as the predominant form. A 100-fold higher methotrexate concentration was required to detect methotrexate uptake and polyglutamylation in the transport defective parent MTX(r)A line, demonstrating that diffusion or an unidentified low affinity route also supports polyglutamylation. Since the folate receptor and the reduced folate carrier achieve nearly identical rates of polyglutamylation despite very different mechanisms of methotrexate delivery, the data suggest that transport-mediated substrate channeling to folylpolyglutamate synthetase is unlikely to play a role in tetrahydrofolate metabolism. This study supports the notion that it is the intracellular concentration of methotrexate achieved within the cell that drives polyglutamylation irrespective of its route of entry.

KW - folate receptor

KW - L1210

KW - methotrexate

KW - polyglutamylation

KW - reduced folate carrier

KW - transport

UR - http://www.scopus.com/inward/record.url?scp=0008195538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0008195538&partnerID=8YFLogxK

U2 - 10.1016/0006-2952(96)00347-4

DO - 10.1016/0006-2952(96)00347-4

M3 - Article

C2 - 8765468

AN - SCOPUS:0008195538

VL - 52

SP - 703

EP - 712

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 5

ER -